drugset / Trial / NCT07082114
A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multicenter, randomized, double-blind, active-controlled, parallel-group study, which aims to provide data on the efficacy and safety of HDM1002 tablets compared with dapagliflozin in adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin.
Timeline
- Start
- 2025-07-14
- Primary completion
- 2027-02-16
- Completion
- 2027-05-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dapagliflozin | Small molecule | 10 mg | Oral |
| Subject | HDM1002 | Unknown | 100 mg | Oral |
| Subject | HDM1002 | Unknown | 200 mg | Oral |
| Subject | HDM1002 | Unknown | 400 mg | Oral |